Emergent Biosolutions (NYSE: EBS) net income
Emergent Biosolutions reported a net profit of $52.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $190.6m. Its net margin was 7.1%. Earnings per share were $0.98.
Emergent Biosolutions's best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2021, −28.2%. It reported a loss in 3 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $52.6m | — | 7.1% | $0.98 |
| 2024 | −$190.6m | — | −18.3% | −$3.60 |
| 2023 | −$760.5m | — | −72.5% | −$14.85 |
| 2022 | −$211.6m | −196.4% | −18.9% | −$4.22 |
| 2021 | $219.5m | −28.2% | 12.4% | $4.10 |
| 2020 | $305.8m | +461.1% | 19.4% | $5.79 |
| 2019 | $54.5m | −13.1% | 4.9% | $1.06 |
| 2018 | $62.7m | −24.1% | 8.0% | $1.25 |
| 2017 | $82.6m | +59.5% | 14.7% | $1.98 |
| 2016 | $51.8m | — | 10.6% | $1.29 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Emergent Biosolutions net income compared with its sector
By net income for its latest fiscal year, Emergent Biosolutions ranks 132nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Emergent Biosolutions, 7.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 130th | Progyny | $58.5m | 4.5% |
| 131st | LeMaitre Vascular | $57.7m | 23.1% |
| 132nd | Emergent Biosolutions | $52.6m | 7.1% |
| 133rd | Repligen | $48.9m | 6.6% |
| 134th | MiMedx Group | $48.6m | 11.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Emergent Biosolutions
- How much did Emergent Biosolutions earn in fiscal 2025?
- Emergent Biosolutions reported a net profit of $52.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $190.6m.
- What are the earnings per share of Emergent Biosolutions?
- They were $0.98 in fiscal 2025, compared with −$3.60 in fiscal 2024.
- What is the net margin of Emergent Biosolutions?
- In fiscal 2025 its net profit was 7.1% of its revenue.
- What was the most profitable year for Emergent Biosolutions?
- Of its last 10 fiscal years, fiscal 2020, with $305.8m.
- Where does Emergent Biosolutions rank in its sector by net income?
- It ranks 132nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Emergent Biosolutions come from?
- From the annual report (Form 10-K) that Emergent Biosolutions files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Emergent Biosolutions files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Emergent Biosolutions: the Emergent Biosolutions page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.